11 February 2020 – EMA’s human medicines committee (CHMP) recommended to grant an EU marketing authorization for Rybelsus (semaglutide) for the treatment of adults with insufficiently controlled type 2 diabetes in order to improve glycaemic control as an adjunct to diet and exercise. Rybelsus is the first glucagon-like peptide (GLP-1) receptor agonist treatment which was developed for oral use. For further information, see here.